These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36171533)

  • 1. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis.
    Lei Q; Yan X; Zou H; Jiang Y; Lai Y; Ung COL; Hu H
    Discov Oncol; 2022 Sep; 13(1):95. PubMed ID: 36171533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis.
    Zou H; Lei Q; Yan X; Lai Y; Ung COL; Hu H
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
    Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
    Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
    Wang Q; Yu J; Sun X; Li J; Cao S; Han Y; Wang H; Yang Z; Li J; Hu C; Zhang Y; Jin L
    Crit Rev Oncol Hematol; 2024 Dec; 204():104522. PubMed ID: 39332750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
    Huang D; Ke L; Cui H; Li S
    BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Efficacy and Safety between Immune Checkpoint Inhibitors and Targeted Drugs in Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Su C; Liao Z; Wang Z; Pei Y; Li W; Liu J
    Comb Chem High Throughput Screen; 2024 Jun; ():. PubMed ID: 38920069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Jiang P; Chen C; Tian J; Yang F; Jiang ZY; Hu AX; Liu B
    Acad Radiol; 2024 Oct; ():. PubMed ID: 39384510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Feng J; Zhao Y; Zhai L; Zhou J
    Medicine (Baltimore); 2024 May; 103(18):e38037. PubMed ID: 38701263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
    JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
    PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Liu W; Quan B; Lu S; Tang B; Li M; Chen R; Ren Z; Yin X
    Front Oncol; 2021; 11():771045. PubMed ID: 35004289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma.
    Han F; Wang XH; Xu CZ
    World J Gastrointest Oncol; 2024 Jul; 16(7):3308-3320. PubMed ID: 39072161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis.
    Wu Z; Zhou P; Zhao Y; Wang J; Gao S
    Transl Cancer Res; 2024 May; 13(5):2451-2463. PubMed ID: 38881944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.